Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...

A new partnership that fully aligns with Syensqo’s global innovation strategy to expand into new bio-based technologies to ...

The World Health Organization and St Jude Children's Research Hospital have kicked off a programme to distribute cancer ...

Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...

ATLANTA - Femasys Inc. (NASDAQ:FEMY), a biomedical company specializing in women's health, has announced the UK regulatory approval of three of its products: the FemaSeed Intratubal Insemination ...

With over 5 million concussions occurring annually in the U.S. alone, there is a significant unmet need for effective diagnostic and therapeutic solutions. This partnership positions Oragenics and ...

Quincy Partnership for Youth is working to reduce substance use and build stronger community bonds through education, ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

GNA-The Ghana Food and Drugs Authority (FDA) has spearheaded a joint initiative with National Regulatory Authorities (NRAs) ...

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.

Egypt’s pharmaceutical industry produces over 90% of its medicines domestically and exports to more than 100 countries.

Hims & Hers, a San Francisco-headquartered telehealth company, ran its controversial Super Bowl commercial despite multiple ...